AMRYT PHARMA PLC - SPNR ADR (AMYT)
US03217L1061 - ADR
Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc
/PRNewswire/ -- Chiesi Farmaceutici S.p.A. ("Chiesi"), an international, research-focused biopharmaceuticals and healthcare group, today announced the...
Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc
Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc
Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc Acquisition positions Chiesi to expand patient access to approved treatments and...
High Court of Justice of England and Wales Sanctions Scheme of Arrangement
Amryt Pharma Shareholders approve acquisition of Amryt Pharma by Chiesi Farmaceutici
Amryt Pharma Shareholders approve acquisition of Amryt Pharma by Chiesi Farmaceutici
Amryt Pharma Shareholders approve acquisition of Amryt Pharma by Chiesi Farmaceutici Transaction Expected to Close in Q2 2023 Dublin, Ireland, March 22,...
AMYT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Amryt Pharma Plc Is Fair to Shareholders
AMRYT PUBLISHES SCHEME CIRCULAR AND ANNOUNCES THE SHAREHOLDER MEETINGS TO CONSIDER AND VOTE ON THE CHIESI ACQUISITION WILL BE HELD ON MARCH 22, 2023
AMRYT PUBLISHES SCHEME CIRCULAR AND ANNOUNCES THE SHAREHOLDER MEETINGS TO CONSIDER AND VOTE ON THE CHIESI ACQUISITION WILL BE HELD ON MARCH 22, 2023 ...
Why Shares of Amryt Pharma Jumped This Week
A takeover bid by an Italian pharmaceutical and healthcare company boosted Amryt's shares.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMYT, CINC, ALBO
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
AMYT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Amryt Pharma Plc Is Fair to Shareholders
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We're starting off the week with a look at the biggest pre-market stock movers traders need to know about on Monday morning!
Chiesi Farmaceutici S.p.A. to acquire Amryt Pharma (NASDAQ:AMYT)
Chiesi Farmaceutici S.p.A. to acquire Amryt Pharma (AMYT) for total transaction value of ~$1.25B in upfront consideration, representing a 107% premium to Amryt ADS' closing price on...
Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc
Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc
Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc - Transaction expands Chiesi’s rare disease medicine...
Amryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide in HoFH
Amryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide in HoFH
Amryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide in HoFH DUBLIN, Ireland, and Boston MA, January 5, 2023, Amryt...
COMP Adopts Positive Opinion on Orphan Designation for Mycapssa® for the Treatment of Carcinoid Syndrome Associated with Neuroendocrine Tumors
COMP Adopts Positive Opinion on Orphan Designation for Mycapssa® for the Treatment of Carcinoid Syndrome Associated with Neuroendocrine Tumors DUBLIN,...
European Commission approves Mycapssa® for the treatment of Acromegaly
European Commission approves Mycapssa® for the treatment of Acromegaly Mycapssa® will be the first and only oral somatostatin analog approved in the EU ...
European Commission approves Mycapssa® for the treatment of Acromegaly
Amryt Announces New Patent for Mycapssa®
Amryt Announces New Patent for Mycapssa® DUBLIN, Ireland, and Boston MA, November 30, 2022 Amryt (Nasdaq: AMYT), a global, commercial-stage...